The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …

Background Erlotinib is an orally active antitumor agent. Analyses in vitro using human liver
microsomes and recombinant enzymes showed that erlotinib was metabolized primarily by …

What is known and objective The efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR‐TKIs) in patients diagnosed with non–small‐cell lung cancer (NSCLC) has …

Background Erlotinib induced skin toxicity has been associated with clinical benefit in
several tumour types. This phase II study evaluated the efficacy of erlotinib, dose escalated …

We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in
patients with advanced non-small cell lung cancer. Eligible studies included randomized …

Purpose Although several studies have examined tyrosine kinase inhibitor (TKI)-induced
hepatotoxicity, the majority of patients in those studies displayed low-grade (grade I–II) …

For advanced non‑small‑cell lung cancer (NSCLC) with mutations to the epidermal growth
factor receptor (EGFR), EGFR tyrosine kinase inhibitors, including erlotinib are indicated for …

Background: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor
receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer …

Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a
monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for …

Purpose Hepatic injury is a common side effect following tyrosine kinase inhibitor (TKI)
therapy and our understanding usually comes from clinical trials. In this retrospective study …